Quoin Pharmaceuticals
QNRX
3 hedge funds and large institutions have $383K invested in Quoin Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more funds holding
Funds holding: 2 → 3 (+1)
2.52% more ownership
Funds ownership: 0% → 2.52% (+2.5%)
59% less capital invested
Capital invested by funds: $937K → $383K (-$554K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$903K |
| 2 |
Renaissance Technologies
New York
|
+$387K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$129K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$240K |
QNRX Hedge Fund Activity: Q4 2021 in Review
3 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q4 2021, worth a combined $383K — down 59% from $937K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new QNRX positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $903K. The largest seller was Geode Capital Management, exiting entirely with an estimated $240K sold.
- 3 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q4 2021, up from 2 in Q3 2021.
- Funds reported $383K of Quoin Pharmaceuticals stock for Q4 2021, down 59% quarter-over-quarter.
- 2 funds opened new Quoin Pharmaceuticals positions in Q4 2021 and 1 closed out, a net change of +1 holder.
- The largest Quoin Pharmaceuticals buyer in Q4 2021 was Morgan Stanley, an estimated $903K added.
- The largest Quoin Pharmaceuticals seller in Q4 2021 was Geode Capital Management, an estimated $240K sold.
Based on aggregated 13F filings for Q4 2021.